開拓藥業(9939.HK)為何跳水暴跌近40%?
格隆匯9月24日丨開拓藥業(9939.HK)盤中一度跳水暴跌近40%至41.5港元,股價創今年4月以來新低,成交額放大至逾10億港元,市值一度跌至161億港元。此前有消息稱,國內在研新冠特效藥——開拓藥業的普克魯胺已率先在美國、南美洲(含巴西)、歐盟、亞洲等國家和地區進行新冠治療的三項全球多中心III期臨牀試驗。開拓藥業曾在今年3月披露一項巴西臨牀試驗結果顯示,普克魯胺能將重症新冠患者的死亡風險降低92%。開拓藥業的股價也一度因“新冠特效藥普克魯胺”從3月初的17港元暴漲至7月份最高時的86港元。有業內人士認為,開拓藥業今日盤中這種程度(近40%)的跳水,有可能是普克魯胺的3期臨牀試驗結果不理想。實際上,開拓藥業關於普克魯胺的信息披露此前曾遭到過質疑。有專家曾表示,藥物從機制上看,普克魯胺與治療新冠病毒幾乎沒有關聯;而開拓藥業美國一位臨牀試驗負責人也否認自己對該試驗知情。另外還值得注意的是,開拓藥業9月8日曾遭珠海格力集團有限公司在場外以每股均價78.00港元減持500萬股,涉資約3.9億港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.